Q-Line Biotech NSE SME IPO review

  • The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
  • It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
  • As the company has no listed peers, it is trying to extract fancy price for its IPO.
  • Based on its overall financial data, the issue appears fully priced.
  • Well-informed investors may park moderate funds for long term.
Dilip Davda

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges. 

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies. 

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Q-Line Biotech IPO

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share.  The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes. 

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr. 

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained. 

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended Revenue Expense PAT Assets
2023 ₹184.81 ₹154.97 ₹32.10 ₹251.58
2024 ₹206.45 ₹175.85 ₹34.44 ₹339.25
2025 ₹322.58 ₹261.43 ₹28.13 ₹455.49
Dec 2025 ₹236.50 ₹186.96 ₹38.69 ₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects. 

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company Face Value (₹) EPS basic (₹)Ā  EPS Diluted (₹) RONW (%) P/E Ratio NAV (₹)
Powerica Limited 5 15.26Ā  15.26 15.37 %Ā  24.45 99.76
Listed Peers
Cummins India Limited 2 72.15Ā  72.15 26.45% 64.13Ā  272.78
Kirloskar Oil Engines Limited 2 33.71 33.60 15.85% 43.24 212.60
NTPC Green Energy Limited 10 0.67 0.67 2.58% 129.40 21.88
Acme Solar Holdings Limited 2 4.55 4.53 5.59% 50.74Ā  74.54
Adani Green Energy Limited 10 8.37 8.37 11.90%Ā  101.53Ā  76.62
Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion
Q-Line Biotech IPO FAQs
1. What is Q-Line Biotech IPO? āŒ„
Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.
2. When Q-Line Biotech IPO will open for subscription? āŒ„
The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.
3. What is Q-Line Biotech IPO Investors Portion? āŒ„
The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.
4. How to Apply the Q-Line Biotech IPO? āŒ„
You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.
5. What is Q-Line Biotech IPO Issue Size? āŒ„
Q-Line Biotech IPO issue size is ₹214 crores.
6. What is Q-Line Biotech IPO Price Band? āŒ„
Q-Line Biotech IPO Price Band is ₹326 to ₹343.
7. What is Q-Line Biotech IPO Lot Size? āŒ„
The minimum bid is 800 Shares with ₹2,74,400 amount.
8. What is the Q-Line Biotech IPO Allotment Date? āŒ„
Q-Line Biotech IPO allotment date is May 26,2026.
9. What is the Q-Line Biotech IPO Listing Date? āŒ„
Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Care Ratings Buyback 2022 Record Date, Price & Ratio Details

Care Ratings buyback 2022 is to be announced on July 20, 2022. The Care Ratings buyback open date is November 18.Ā Care Ratings buyback record date is September 14. The investor should buy the Care Ratings shares before the record date to get eligibility for the buyback.

Care Ratings Buyback of ₹122 crores approved by the board of directors at the meeting was held on July 20, 2022. Care Ratings Buyback will be done via the Tender Offer route through the stock exchange mechanism. The board of directors of the company approved the buyback by the Company of its fully paid-up equity shares having a face value of ₹10 each equity share at a price not exceeding ₹515 per Equity Share and for an aggregate amount not exceeding ₹121 crores from the shareholders. Check out Care Ratings Buyback 2022 details below:

CareEdge Ratings (CARE Ratings Ltd) commenced operations in April 1993 and in almost 3 decades has established itself as one of the leading credit rating agencies in India. CareEdge Ratings has emerged as the leading agency for covering many rating segments including manufacturing, infrastructure, a financial sector including banks, and non-financial services, among others. The company has an established track record of rating companies over almost three decades and has had a pivotal role to play in developing bank debt and capital market instruments including CPs, corporate bonds and debentures, and structured credit. CareEdge is recognized for being a knowledge-based group and provides near real-time research on all domestic and global economic developments. Special studies and surveys are also undertaken on different subjects. The Industry Research team tracks and publishes sector reports on an ongoing basis. CareEdge Ratings’ (CARE Ratings Ltd.) wholly-owned subsidiaries include CARE Advisory, Research & Training Ltd. and CARE Risk Solutions Pvt Ltd. In the global arena, CARE Ratings Ltd. is a partner in ARC Ratings, an international credit rating agency. The company also has subsidiaries in Mauritius ‘CareEdge Ratings (Africa) Private Limited (CRAF)’ and in Nepal ‘CareEdge Ratings Nepal’. The company has a strategic alliance with Japan Credit Ratings Agency (JCR) and MoU with Russian rating agency ACRA.

    Care Ratings Buyback 2022 Dates

    Ā Buyback Meeting Date: Ā July 20, 2022
    Ā Buyback Announcement Date: Ā July 20, 2022
    Ā Buyback RecordĀ Date: Ā September 14, 2022
    Ā Buyback Open Date: Ā November 18, 2022
    Ā Buyback Close Date: Ā December 1, 2022
    Ā Finalization of Buyback Acceptance: Ā December 9, 2022

    Care Ratings Buyback 2022 Offer Details

    Care Ratings buyback ofĀ 23,68,000Ā equity shares at a price of ₹515 per equity share. The buyback offers not to exceed ₹122 crores of the total buyback offer size.

    Ā Offer Amount:  ₹122 Crores
    Ā Number of Shares: Ā 23,68,000Ā Equity Shares
    Ā Face Value:  ₹10Ā per equity share
    Ā Buyback Price:  ₹515Ā per equity share
    Ā Listing: Ā BSE & NSE
    Ā Buyback Type: Ā Tender Offer
    Ā Letter of Offer: Ā Click Here

    Care Ratings Buyback 2022 Acceptance Ratio

    The investor should buy around [.] shares at a current market price of ₹[.] (as of [.]). The calculation will be ₹2,00,000 / ₹[.] buyback price = [.] shares.

    Acceptance Ratio Investment Shares Buyback Profit
    33% ₹[.] [.] ₹[.]
    50% ₹[.] [.] ₹[.]
    75% ₹[.] [.] ₹[.]
    100% ₹[.] [.] ₹[.]

    Care Ratings Financial Report

    Ā  ₹ in Crores
    Year Revenue Expense PAT
    2020 ₹250 ₹143 ₹80.50
    2021 ₹251 ₹131 ₹85.83
    2022 ₹247 ₹133 ₹84.47

    How to Participate in Care Ratings Buyback 2022

    The investors are eligible for the buyback scheme who have Care Ratings shares in their Demat account as the [.]. Eligible Share Holders can participate in the Care Ratings Buyback 2022 scheme as per the opening form by selling their shares. The payment will be given as per the accepted shares by the company under the Care Ratings buyback scheme.

    Care Ratings Buyback 2022 Registrar

    KFin Technologies Limited
    Selenium Tower B, Plot No. 31-32,
    Gachibowli, Financial District,
    Nanakramguda, Seri, Hyderabad 500032, Telangana
    Tel: 040-67161500, 67162222, 33211000
    Email: einward.ris@karvy.com
    Website: http://www.kfintech.com

    Care Ratings Buyback 2022 Lead Managers

    • DAM Capital Advisors Ltd

    Care Ratings Company Address

    CARE Ratings Limited
    4th Floor, Godrej Coliseum,
    Somaiya Hospital Road,
    Off Eastern Express Highway, Sion (E), – 400 022
    Phone: +91-22-6754 3456
    Email: care@careedge.in
    Website: http://www.careedge.in/

    How to Apply the Care Ratings Buyback through Zerodha?

    Log in to Console in Zerodha Website or in Application. Go to Portfolio and Click on Corporate Actions. You will see the Company Name “Care Ratings”. Click on Place Order. Enter your Quantity and submit Care Ratings Buyback Application Form.Ā Open Demat Account with Zerodha.

    How to Apply the Care Ratings Buyback through Upstox?

    Log in to Upstox Application with your credentials. Select the Account Section. You will see the Company Name “Care Ratings”. Click on Care Ratings Stock for Buyback. Enter your Quantity and submit Care Ratings Buyback Application Form.Ā Open Demat Account with Upstox.

    How to Apply the Care Ratings Buyback through Paytm Money?

    Log in to Paytm Money Application with your credentials. Select the Care Ratings. Enter your Quantity and submit Care Ratings Buyback Application Form.Ā Open Demat Account with PaytmMoney.

    Care Ratings Buyback 2022 FAQs

    When is Care Ratings Buyback 2022 Record Date?

    Care Ratings buyback 2022 record date is September 14, 2022.

    When is Care Ratings Buyback 2022 Open Date?

    Care Ratings buyback 2022 open date is November 18, 2022.

    What is Care Ratings Buyback 2022 Price?

    The company has fixed the price at ₹515 per share.

    What is Care Ratings Buyback size?

    Care Ratings buyback size is ₹122 crores.

    How to apply for Care Ratings Buyback 2022?

    As per the record date you need to have Care Ratings shares in your Demat account. You can participate in buyback after having the stock in your account.Follow IPO Watch for the upcoming IPO newsĀ and their reviews, also keep following us onĀ Twitter,Ā Facebook, andĀ Instagram. For our latest videos, subscribe to ourĀ YouTube channel.

    Table of Contents

    Picture of Jagat Joshi

    Jagat Joshi

    Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.
    Picture of Jagat Joshi

    Jagat Joshi